Biosimilars and Rheumatoid Arthritis | Making the switch

Published: 23 Mar 2018

The Oxford Academic Health Science Network (Oxford AHSN) and Sandoz, have developed an informative animation on biosimilars with input from individuals living with inflammatory arthritis and in partnership with the National Rheumatoid Arthritis Society.

The aim of this film is to inform people in an easy-to-understand, accessible format:

  • What biosimilars are
  • Why they have been approved for use in the UK
  • What that may mean for patients and health professionals.

NRAS believes biosimilars to be an important addition to available treatments for autoimmune conditions including rheumatoid arthritis. They are a lower cost alternative to originator drugs. This allows the NHS to make potential savings when switching patients from an originator treatment to a biosimilar.

This animation would be an ideal aid for health professionals when discussing switching to a biosimilar with patients. We encourage health professionals to signpost their patients to this excellent resource which will help reduce any concerns or anxieties they individual may have.